Legend Biotech Announces FDA Clearance of IND Application for LB2102 in Extensive Stage Small Cell Lung Cancer
Retrieved on:
Monday, November 21, 2022
Oncology, FDA, Health, Clinical Trials, Pharmaceutical, Biotechnology, FDA, Lung cancer, Clinical trial, Squamous cell carcinoma, Small-cell carcinoma, Drug, Cancer, Government, NK, Large cell neuroendocrine carcinoma of the lung, Prostate cancer, SNAI1, Investigational New Drug, Safety, Security (finance), IND, SCLC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Disease, Maintenance, Annual report, Legend, Wilms' tumor, Therapy, Regulation, COVID-19, Diagnosis, American Cancer Society, Food, Patient, United, Pharmaceutical industry, Uranium, Vaccine
On average, only seven percent of patients with SCLC are alive five years after receiving their diagnosis, said Lida Pacaud, M.D., Vice-President of Clinical Development at Legend Biotech.
Key Points:
- On average, only seven percent of patients with SCLC are alive five years after receiving their diagnosis, said Lida Pacaud, M.D., Vice-President of Clinical Development at Legend Biotech.
- Legend Biotech specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.
- 1 Furuta M. DLL3 regulates the migration and invasion of small cell lung cancer by modulating SNAI1.
- Small cell lung cancer: where do we go from here?